Evidence map›Paper›PMID 41357604›Full record

ArticleFrontiers in oncology2025

LncRNA

Xiao Hu, Tianhang Xie, Xiao Xiao, Yuhua Mei

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao Hu *Frontiers Science Center for Disease-related Molecular Network, Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tianhang Xie *Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiao XiaoDepartment of Urology, Chongqing University Fuling Hospital, Chongqing, China.
Yuhua MeiDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bladder cancer (BCa) is one of the most prevalent genitourinary malignancies with high recurrence worldwide. A lack of reliable prognostic biomarkers and effective therapeutic targets hinders its treatment. Emerging evidence indicates that long noncoding RNAs (lncRNAs) are involved in human cancers, including BCa. While lncRNAs hold enormous promise, their specific roles and mechanisms in BCa remain largely unexplored. Here, we identify the lncRNA ELDR as a pivotal oncogenic driver in BCa. Methods: RT-qPCR was used to analyze the expression patterns of ELDR, miR-1343-3p and TRIM44. CCK-8, colony formation, EdU, and Transwell assays were used to detect the effect of ELDR on cell proliferation, migration, and invasion. The association between ELDR, miR-1343-3p and TRIM44 was analyzed by bioinformatics analysis and dual-luciferase reporter assay. Finally, the role of the ELDR-miR-1343-3p-TRIM44 axis in bladder cancer cell behavior was demonstrated. Results and Discussion: ELDR is significantly upregulated in BCa tissues, and its high expression correlates with aggressive clinicopathological features and predicts poor prognosis in BCa patients. Functional experiments demonstrate that ELDR enhances BCa cell proliferation, colony formation, migration, and invasion in vitro and accelerates tumor growth in vivo. Mechanistically, ELDR functions as a competitive endogenous RNA (ceRNA) by sequestering tumor-suppressive miR-1343-3p in the cytoplasm, which consequently leads to the upregulation of the oncogene TRIM44. Our findings unveil the ELDR/miR-1343-3p/TRIM44 axis as a crucial pathway in BCa progression, establishing ELDR as a promising prognostic biomarker and an attractive candidate for the development of targeted therapies.

Indexed as

bladder cancerceRNAELDRmiR-1343-3pTRIM44

Identifiers

PMID41357604
PMCPMC12678138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.